New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 5, 2014
07:17 EDTCYCCCyclacel Pharmaceuticals issued new Japanese patent
Cyclacel Pharmaceuticals announced that the Japanese Patent and Trademark Office issued two patents broadening the exclusivity of sapacitabine, the company's lead clinical candidate. Japanese Patent 5443763 claims novel pharmaceutical formulations of sapacitabine. Japanese Patent 5457196 claims methods of treating cancer comprising sapacitabine in combination with histone deacetylase inhibitors. Equivalent patents have been granted in the United States and other countries.
News For CYCC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 9, 2014
07:10 EDTCYCCCyclacel announces DSMB recommendation to continue Sapacitabine Phase 3 trial
Cyclacel Pharmaceuticals announced that the independent Data and Safety Monitoring Board, or DSMB, for the company's Phase 3 SEAMLESS study in acute myeloid leukemia, or AML, has completed its fourth planned safety review and recommended that the study should continue as planned without any modifications. The DSMB reviewed available data from 317 randomized patients with at least 60 days of follow-up and noted that no safety or efficacy concerns were identified.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use